MUMBAI, India, Oct. 5 -- Intellectual Property India has published a patent application (202647114397 A) filed by Hangzhou Zhongmeihuadong Pharmaceutical Co. on September 24, 2026, for Anti-Mucin 17 Antibody, Conjugate Thereof And Use Thereof.
Inventors include Shu, Qingyu; Lu, Kuan Number; Xia, Yan; Qin, Zhaofeng; Zhao, Shengxing; and Liu, Dongzhou.
The application for the patent was published on October 02, 2026, under issue no. 40/2026.
Abstract: An antibody specifically binding to mucin 17(MUC17), an antibody-drug conjugate and a method for using same, and a composition containing a molecule and a detection system. The anti-MUC17 antibody, the conjugate thereof, or the composition thereof can be used as an independent therapy for the treatment of cancer/tumor, etc., or in combination with other therapies/or other anti-cancer agents.
Disclaimer: Curated by HT Syndication.
